Pembrolizumab-Induced Adrenal Insufficiency Presenting Eight Months After Cessation of Treatment

Pembrolizumab is a monoclonal antibody that functions as an immune checkpoint inhibitor. It is an FDA-approved immunotherapy used to treat various malignancies. With its wide use in cancer therapy, there are many known side effects. It is a common cause of endocrinopathies such as thyroid disease an...

Descripción completa

Detalles Bibliográficos
Autores principales: Zilberman, Stephanie, Rafii, Daniel C, Giunta, Judith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Endocrinology/Diabetes/Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374333/
https://www.ncbi.nlm.nih.gov/pubmed/37519548
http://dx.doi.org/10.7759/cureus.41049
_version_ 1785078752006373376
author Zilberman, Stephanie
Rafii, Daniel C
Giunta, Judith
author_facet Zilberman, Stephanie
Rafii, Daniel C
Giunta, Judith
author_sort Zilberman, Stephanie
collection PubMed
description Pembrolizumab is a monoclonal antibody that functions as an immune checkpoint inhibitor. It is an FDA-approved immunotherapy used to treat various malignancies. With its wide use in cancer therapy, there are many known side effects. It is a common cause of endocrinopathies such as thyroid disease and adrenal insufficiency (AI). AI has been most commonly reported during active treatment cycles with pembrolizumab, as well as quickly after the termination of treatment. However, we describe a case of pembrolizumab-induced AI with an onset at eight months following the discontinuation of treatment and discuss prompt treatment when AI is diagnosed.
format Online
Article
Text
id pubmed-10374333
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-103743332023-07-28 Pembrolizumab-Induced Adrenal Insufficiency Presenting Eight Months After Cessation of Treatment Zilberman, Stephanie Rafii, Daniel C Giunta, Judith Cureus Endocrinology/Diabetes/Metabolism Pembrolizumab is a monoclonal antibody that functions as an immune checkpoint inhibitor. It is an FDA-approved immunotherapy used to treat various malignancies. With its wide use in cancer therapy, there are many known side effects. It is a common cause of endocrinopathies such as thyroid disease and adrenal insufficiency (AI). AI has been most commonly reported during active treatment cycles with pembrolizumab, as well as quickly after the termination of treatment. However, we describe a case of pembrolizumab-induced AI with an onset at eight months following the discontinuation of treatment and discuss prompt treatment when AI is diagnosed. Cureus 2023-06-27 /pmc/articles/PMC10374333/ /pubmed/37519548 http://dx.doi.org/10.7759/cureus.41049 Text en Copyright © 2023, Zilberman et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Endocrinology/Diabetes/Metabolism
Zilberman, Stephanie
Rafii, Daniel C
Giunta, Judith
Pembrolizumab-Induced Adrenal Insufficiency Presenting Eight Months After Cessation of Treatment
title Pembrolizumab-Induced Adrenal Insufficiency Presenting Eight Months After Cessation of Treatment
title_full Pembrolizumab-Induced Adrenal Insufficiency Presenting Eight Months After Cessation of Treatment
title_fullStr Pembrolizumab-Induced Adrenal Insufficiency Presenting Eight Months After Cessation of Treatment
title_full_unstemmed Pembrolizumab-Induced Adrenal Insufficiency Presenting Eight Months After Cessation of Treatment
title_short Pembrolizumab-Induced Adrenal Insufficiency Presenting Eight Months After Cessation of Treatment
title_sort pembrolizumab-induced adrenal insufficiency presenting eight months after cessation of treatment
topic Endocrinology/Diabetes/Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374333/
https://www.ncbi.nlm.nih.gov/pubmed/37519548
http://dx.doi.org/10.7759/cureus.41049
work_keys_str_mv AT zilbermanstephanie pembrolizumabinducedadrenalinsufficiencypresentingeightmonthsaftercessationoftreatment
AT rafiidanielc pembrolizumabinducedadrenalinsufficiencypresentingeightmonthsaftercessationoftreatment
AT giuntajudith pembrolizumabinducedadrenalinsufficiencypresentingeightmonthsaftercessationoftreatment

Ejemplares similares